Importantly, patients with BCL9L or FAT4 mutations did not differ significantly from the rest of the cohort in terms of other clinical or genomic features, including age, TMB, number of mutations in CRC driver genes, CNAs affecting CRC driver genes, or number of prior treatments (Fig. S1B). This evidence concerns the gene BCL9L and colorectal carcinoma.